All In Biotech

Drug Trial Radar · NCT06411860

A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants

A Randomized, Placebo- and Positive-controlled, Crossover Study to Assess the Effect of Olpasiran (AMG 890) on QT/QTc Intervals in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Sep 12, 2024

Primary completion

Nov 29, 2024

Study completion Dec 11, 2024

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
May 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the study is: • To assess the effects of a single therapeutic and supratherapeutic dose of olpasiran on the placebo-corrected change from baseline in QT corrected for heart rate (ΔΔQT)/QTc interval in healthy participants.

Conditions

  • Basic Science

Interventions

  • PlaceboOther

    Participants will receive a subcutaneous (SC) injection of placebo.

  • OlpasiranDrug

    Participants will receive a SC injection of olpasiran at dose level 1 or 2.

  • MoxifloxacinDrug

    Participants will receive a single dose of moxifloxacin as an oral tablet by mouth.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Placebo-corrected Change From Baseline in QT Corrected for Heart Rate (HR) Interval Based on the Fridericia Correction (QTcF) (ΔΔQTcF) After Olpasiran DosingTime frame: Day 3 of Treatment Period 4 (up to approximately 9.5 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fortrea Clinical Research Unit Limited - Leeds

    Leeds, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.